Sign in
TerminatedNo phase

ESKETamine for FIBromyalgia Treatment

Key facts

Who runs it
Grand Hôpital de Charleroi
Where
Belgium1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
23 people enrolled
Started
10 Oct 2020
Ended
30 Sept 2024
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Active comparator
  • S-Ketamine Low dose
  • S-Ketamine High dose
Record updated
20 November 2024
Why it stopped
Lack of recruitment.

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • patients suffering from chronic pain (as defined by International Association for the Study of Pain) being diagnosed as fibromyalgia according to the American College of Rheumatology 2016 criteria
  • patients qualified for the treatment by S-ketamine as established by our latest clinical practice
  • patients aged 18-65 years old

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Fibromyalgia is a cause of chronic pain, classified by the Internal Classification of Diseases (ICD) as a primary chronic pain with specific diagnostic criteria established by the American College of Rheumatology (ACR). No treatment to its complete cure is available at this time, all treatments having as purpose pain relief and an improvement of quality of life by combining pharmacologic and nonpharmacologic treatments. One of the mechanisms proposed in fibromyalgia is the central sensitisation phenomenon, by which the central nervous system becomes "hypersensitive" to nociceptive or non-nociceptive stimuli. The receptor involved in this phenomenon is the N-methyl-D-aspartate receptor to which ketamine binds. Ketamine has therefore been proposed as a co-treatment in chronic pain with central sensitization phenomena, such as fibromyalgia.

The 3 groups in the trial

  • PlaceboExisting treatment, for comparison

    Clonidine at a dose of 1 microg/kg Magnesium sulfate at a dose of 40 mg/kg

    Treatment: Active comparator

  • S-Ketamine Low doseTreatment being tested

    S-Ketamine at a dose of 0.2 mg/kg

    Treatment: Active comparator and S-Ketamine Low dose

  • S-ketamine High doseTreatment being tested

    S-ketamine at a dose of 0.4 mg/kg

    Treatment: Active comparator and S-Ketamine High dose

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Intravenous Infusions of S-KETAMINE in Fibromyalgia Syndromes: an Exploratory Study.
Publications
Record updated
20 November 2024